Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Allergy and Immunology · Aspirin-Exacerbated Respiratory Disease

Managing the Cycle: Treatment Options for AERD

At a Glance

AERD requires a comprehensive treatment strategy to prevent rapid polyp regrowth. Standard care typically combines endoscopic sinus surgery to clear blockages with long-term maintenance using either daily aspirin desensitization therapy or targeted biologic injections like dupilumab.

Managing AERD (Samter’s Triad) requires more than just standard asthma and allergy treatments. Because it is a metabolic disorder that causes aggressive, lifelong inflammation, the standard of care usually involves a “multi-pronged” approach—combining surgery with a specialized long-term medical strategy to prevent the disease from returning [1][2].

The “Reset”: Endoscopic Sinus Surgery (ESS)

For many patients, the first step is Endoscopic Sinus Surgery (ESS). In AERD, this is often viewed as a “reset” rather than a permanent cure [1].

  • The Goal: Surgery physically clears out the polyps that are blocking your breathing and opens up the sinus cavities [3].
  • The Limitation: Without additional treatment, polyps in AERD patients return much faster and more aggressively than in other types of sinus disease [4][5]. The surgery’s main benefit is that it allows your topical medications (like steroid nasal washes) to actually reach the inflamed tissues [3].

Option 1: Aspirin Desensitization (ATAD)

Aspirin Therapy After Desensitization (ATAD) is a classic treatment for AERD. It involves “training” your body to tolerate aspirin [6][7].

  • The Process: Under strict medical supervision, you are given tiny, increasing doses of aspirin until you can tolerate a full dose without a reaction [7][8].
  • Maintenance: To stay desensitized, you must take a daily dose of aspirin—often ranging from 325 mg to 650 mg twice daily [6][9].
  • Benefits: It can significantly slow the regrowth of polyps and may improve asthma control [7][10].
  • Drawbacks: Some patients find it difficult to tolerate high-dose aspirin daily due to stomach pain, acid reflux, or easy bruising [11][12].

Option 2: Biologic Therapies

The emergence of biologics—medications that target specific proteins in the immune system—has revolutionized AERD care.

  • How it Works: These medications block the specific inflammatory pathways (like IL-4 and IL-13) that cause the overproduction of mucus and polyps [13][14].
  • Efficacy: Dupilumab (Dupixent) is the most widely prescribed biologic for AERD and is highly effective at shrinking polyps. It is particularly known for rapidly restoring the sense of smell in many patients and preventing severe asthma attacks [15][16][17].
  • Other Options: While dupilumab is common, other biologics such as omalizumab (Xolair), mepolizumab (Nucala), or benralizumab (Fasenra) are also utilized to target different parts of the asthma and inflammatory cascade. This ensures you have backup options if one biologic is ineffective [18][14].
  • Preference: Many patients now prefer biologics over aspirin therapy because they require only a self-injection every few weeks and avoid the stomach-related side effects of daily aspirin [19][11].

Deciding on the Right Path

Your care team—usually an allergist and an ENT specialist working together—will help you choose between these options based on your unique situation [20].

  • Aspirin desensitization might be favored if you already need daily aspirin for heart health or have milder symptoms [21][22].
  • Biologics are often the first choice for patients with severe, recurring polyps, total loss of smell, or asthma that isn’t responding to other treatments [23][24].
  • In some very severe cases, doctors may even recommend using both treatments together for maximum control [2][23].

Common questions in this guide

Do I need sinus surgery before starting AERD medication?
Endoscopic sinus surgery is often the first step in AERD treatment. It acts as a reset by physically clearing out polyps, which opens your airway and allows topical medications like steroid nasal washes to reach inflamed tissues.
How does aspirin desensitization work for AERD?
Aspirin Therapy After Desensitization (ATAD) trains your body to tolerate aspirin through tiny, increasing doses under medical supervision. Once desensitized, you must take a daily high-dose aspirin to slow polyp regrowth and control asthma symptoms.
What are the drawbacks of daily aspirin therapy?
Some patients have difficulty tolerating the high daily doses of aspirin required for AERD maintenance. Common side effects can include stomach pain, acid reflux, or easy bruising.
Why might I choose a biologic over aspirin desensitization?
Many patients choose biologics like dupilumab because they only require a self-injection every few weeks, avoiding the stomach issues linked to daily high-dose aspirin. Biologics are also highly effective at treating severe polyps and restoring the sense of smell.
How do I choose the right treatment path for my AERD?
Your care team, which typically includes an allergist and an ENT specialist, will evaluate your specific symptoms, medical history, and lifestyle preferences. Factors like symptom severity, existing heart conditions, and tolerance for daily pills versus injections will guide the decision.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my history of quick polyp recurrence, should we combine surgery with either aspirin desensitization or a biologic?
  2. 2.If I choose aspirin desensitization, what is the best maintenance dose for my specific case (e.g., 325 mg vs. 650 mg twice daily)?
  3. 3.Am I a good candidate for dupilumab, and how quickly can I expect to see improvements in my sense of smell?
  4. 4.If I have stomach issues like GERD, is aspirin desensitization safe for me, or should we favor a biologic?
  5. 5.Will the use of a biologic reduce my need for oral steroids like prednisone?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Update on aspirin exacerbated respiratory disease with chronic rhinosinusitis.

    Gandre JR, Ledford DK

    Current opinion in allergy and clinical immunology 2025; (25(1)):10-18 doi:10.1097/ACI.0000000000001054.

    PMID: 39641754
  2. 2

    [Does aspirin therapy after desensitization still have a role in treatment of chronic rhinosinusitis with nasal polyposis in the era of biologics?]

    Klimek F, Förster-Ruhrmann U, Hagemann J, et al.

    HNO 2024; (72(7)):484-493 doi:10.1007/s00106-024-01431-0.

    PMID: 38409556
  3. 3

    The role of large cavity sinus surgery in the management of chronic rhinosinusitis in non-steroidal anti-inflammatory drug exacerbated respiratory disease: a single-centre experience and long-term outcomes.

    Pendolino AL, Bandino F, Navaratnam A, et al.

    The Journal of laryngology and otology 2023; (137(8)):883-889 doi:10.1017/S0022215122002468.

    PMID: 36443933
  4. 4

    Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.

    Stevens WW, Schleimer RP

    Immunology and allergy clinics of North America 2016; (36(4)):669-680 doi:10.1016/j.iac.2016.06.004.

    PMID: 27712762
  5. 5

    Phenotypic associations of medical polypectomy and revision surgery following endoscopic sinus surgery: a retrospective study of a single-centre experience in Scotland.

    Misirovs R, Chan R, Stewart K, Lipworth B

    The Journal of laryngology and otology 2023; (137(11)):1277-1284 doi:10.1017/S0022215123000853.

    PMID: 37212124
  6. 6

    Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD.

    Huang GX, Palumbo ML, Singer JI, et al.

    The journal of allergy and clinical immunology. In practice 2019; (7(5)):1647-1649 doi:10.1016/j.jaip.2019.02.037.

    PMID: 30877073
  7. 7

    Aspirin Desensitization: Faster Protocols for Busy Patients.

    White AA, Stevenson DD

    The journal of allergy and clinical immunology. In practice 2019; (7(4)):1181-1183 doi:10.1016/j.jaip.2018.10.019.

    PMID: 30961839
  8. 8

    One- versus 2-day aspirin desensitization in aspirin exacerbated respiratory disease: A quality improvement project.

    Gansert E, Morgenstern-Kaplan D, Donaldson AM, et al.

    The journal of allergy and clinical immunology. Global 2023; (2(4)):100158 doi:10.1016/j.jacig.2023.100158.

    PMID: 37781671
  9. 9

    The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis.

    Arshi S, Darougar S, Nabavi M, et al.

    Iranian journal of allergy, asthma, and immunology 2021; (20(3)):287-293 doi:10.18502/ijaai.v20i3.6330.

    PMID: 34134450
  10. 10

    Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease.

    Mortazavi N, Esmaeilzadeh H, Abbasinazari M, et al.

    Iranian journal of pharmaceutical research : IJPR 2017; (16(4)):1639-1647.

    PMID: 29552073
  11. 11

    Real-World Treatment Patterns in AERD: An Analysis of ATAD, Biologics, and Combination Therapy.

    Kumar N, Pace T, Gomes PL, et al.

    International forum of allergy & rhinology 2026; (16(1)):99-101 doi:10.1002/alr.70072.

    PMID: 41269030
  12. 12

    Lung function and side effects of Aspirin desensitization: a real world study.

    Heikki T, Anu LH, Annina L, et al.

    European clinical respiratory journal 2021; (8(1)):1869408 doi:10.1080/20018525.2020.1869408.

    PMID: 33520120
  13. 13

    IL-4Rα signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease.

    Chen CC, Buchheit KM, Lee PY, et al.

    The Journal of allergy and clinical immunology 2024; (154(2)):458-467.e3 doi:10.1016/j.jaci.2024.04.020.

    PMID: 38704098
  14. 14

    Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.

    Schneider S, Poglitsch K, Morgenstern C, et al.

    The European respiratory journal 2023; (61(3)) doi:10.1183/13993003.01335-2022.

    PMID: 36549708
  15. 15

    Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.

    Mullol J, Bachert C, Amin N, et al.

    The journal of allergy and clinical immunology. In practice 2022; (10(4)):1086-1095.e5 doi:10.1016/j.jaip.2021.09.037.

    PMID: 34628065
  16. 16

    The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma.

    Nakagome K, Nagata M

    Biomolecules 2024; (14(5)) doi:10.3390/biom14050546.

    PMID: 38785953
  17. 17

    The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.

    Fujieda S, Matsune S, Takeno S, et al.

    The Laryngoscope 2021; (131(6)):E1770-E1777 doi:10.1002/lary.29230.

    PMID: 33226139
  18. 18

    Aspirin-exacerbated respiratory disease in the era of biologics.

    Laidlaw TM

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2025; (135(4)):366-373 doi:10.1016/j.anai.2025.06.001.

    PMID: 40490219
  19. 19

    [Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization : Results of a multicentric study].

    Staufenberg AR, Frankenberger HK, Förster-Ruhrmann U, et al.

    HNO 2024; (72(7)):473-483 doi:10.1007/s00106-024-01433-y.

    PMID: 38466409
  20. 20

    What's New in the Diagnosis and Treatment of Aspirin-Exacerbated Respiratory Disease: A Brief Review.

    Douglas JE, Bosso JV

    American journal of rhinology & allergy 2023; (37(2)):198-206 doi:10.1177/19458924221145254.

    PMID: 40071630
  21. 21

    Clinical Efficacy of Biologics and ATAD in NSAID-Exacerbated Respiratory Disease: A Phenotype-Based Comparative Study.

    Cihanbeylerden M, Kayıkçı H, Tüccar Ç, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(10)):2700-2710.e2 doi:10.1016/j.jaip.2025.07.038.

    PMID: 40752740
  22. 22

    Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: Clinical perspective.

    Bosso JV

    International forum of allergy & rhinology 2021; (11(4)):822-823 doi:10.1002/alr.22709.

    PMID: 33070455
  23. 23

    Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.

    Mullur J, Steger CM, Gakpo D, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2022; (128(5)):575-582 doi:10.1016/j.anai.2022.01.043.

    PMID: 35131410
  24. 24

    Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness.

    Ameer OZ, Mansour GK, Al-Amoudi RS, Abu-Owaimer FM

    Frontiers in pharmacology 2025; (16()):1631321 doi:10.3389/fphar.2025.1631321.

    PMID: 40843371

This page provides educational information about AERD treatment options. Always consult your allergist or ENT specialist to determine the safest and most effective medical or surgical plan for your specific condition.

Get notified when new evidence is published on asthma, nasal polyps, and aspirin intolerance.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.